UCB

Stocks

Real-time Euronext Bruxelles 08:40:39 2026-11-06 am EST			5-day change	1st Jan Change
283.30 ^EUR	-2.38%		+0.57%	+18.61%

12:27am	Berenberg Sees 'Sustainable' Volume-led Growth for UCB into FY27; Estimates Up	MT
Nov. 04	UCB Enters Strategic Collaboration With Cradle To Advance Digital Antibody Engineering Program	CI

Published on 10/07/2026 at 10:36 pm EDT - Modified on 10/08/2026 at 02:38 am EDT

S&P Capital IQ

Presenter Speech
Yvonne Naughton (Executives)

Hello, everyone, and welcome to UCB's EADV Capital Markets Call for Institutional Investors and Analysts. My name is Yvonne Naughton, and I lead the

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

12:27am	Berenberg Sees 'Sustainable' Volume-led Growth for UCB into FY27; Estimates Up	MT
Nov. 04	UCB Enters Strategic Collaboration With Cradle To Advance Digital Antibody Engineering Program	CI
Oct. 27	AlphaValue/Baader Europe Raises Estimates for UCB on Recent FY26 Outlook Upgrade	MT
Oct. 26	UCB: Undercommit and overdeliver – The UCB way
Oct. 26	A Week of Reckoning for Wall Street
Oct. 26	BofA Lifts UCB Price Objective, EPS Forecasts After 'Surprise' FY26 Guidance Upgrade	MT
Oct. 26	Three central banks, three tech giants, and November 3 on the horizon
Oct. 23	AlphaValue/Baader Europe Downgrades UCB to Reduce	MT
Oct. 22	Global markets live: Tesla, Meta, Lockheed Martin, IBM, SpaceX…
Oct. 22	AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination	RE
Oct. 22	UCB: Growth engine isn't out of breath yet
Oct. 22	UCB raises guidance on strength of its two flagship treatments, analysts applaud
Oct. 22	UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook	DJ
Oct. 22	UCB soars on US demand, Hermes loses ground and drags luxury lower
Oct. 22	UCB lifts 2026 outlook again as Bimzelx demand eases investor concerns	RE